ArticleJournal of orthopaedic translation2018
Meta-analysis of urinary C-terminal telopeptide of type II collagen as a biomarker in osteoarthritis diagnosis.
Article in Journal of orthopaedic translation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04557943 (The Level of Cartilage Oligomeric Matrix Protein), which is not on this map. Cited by 16 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Level of Cartilage Oligomeric Matrix Protein (COMP) and Urinary C-Terminal Telopeptides of Type II Collagen (uCTX-II) After Prolotherapy Intervention and The Functional Outcome in Patient With Knee Osteoarthritis
Who cites it
16 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Clinically Relevant Molecular Biomarkers for Use in Human Knee Osteoarthritis: A Systematic Review.Cartilage · 2021Pooled it
- C-Terminal Cross-Linked Telopeptides of Type II Collagen as Biomarker for Radiological Knee Osteoarthritis: A Meta-Analysis.Cartilage · 2020Pooled it
- Pulmonary Rehabilitation Can Improve the Functional Capacity and Quality of Life for Pneumoconiosis Patients: A Systematic Review and Meta-Analysis.BioMed research international · 2020Pooled it
- Two Highly Specific Mouse Monoclonal Antibodies to the Putative C-Telopeptide of Human Collagen XIα1, a Cancer Biomarker.Antibodies (Basel, Switzerland) · 2026Article
- Structural and Molecular Effects of Dextrose on Cartilage: A Scoping Review.Current rheumatology reviews · 2026Article
- Estimation of Serum C-terminal Cross-linked Telopeptide Type II Collagen (CTX II) Level to Diagnose Early Knee Osteoarthritis.Malaysian orthopaedic journal · 2025Article
- AI-Assisted Plasmonic Diagnostics Platform for Osteoarthritis and Rheumatoid Arthritis With Biomarker Quantification Using Mathematical Models.Small (Weinheim an der Bergstrasse, Germany) · 2025Article
- Bone-derived factors mediate crosstalk between skeletal and extra-skeletal organs.Bone research · 2025Review
- Clinical and omics biomarkers in osteoarthritis diagnosis and treatment.Journal of orthopaedic translation · 2025Review
- Maintaining hypoxia environment of subchondral bone alleviates osteoarthritis progression.Science advances · 2023Article
- Effect of growth hormone releasing hormone on chondrocytes of osteoarthritis.The Korean journal of internal medicine · 2022Article
- The CRTAC1 Protein in Plasma Is Associated With Osteoarthritis and Predicts Progression to Joint Replacement: A Large-Scale Proteomics Scan in Iceland.Arthritis & rheumatology (Hoboken, N.J.) · 2021Article
- Biomarkers of Joint Damage in Osteoarthritis: Current Status and Future Directions.Mediators of inflammation · 2021Review
- Mass Spectrometry Imaging as a Potential Tool to Investigate Human Osteoarthritis at the Tissue Level.International journal of molecular sciences · 2020Review
- Can urinary CTX-II be a biomarker for knee osteoarthritis?Arthroplasty (London, England) · 2020Article
- Biomarkers in Painful Symptomatic Knee OA Demonstrate That MRI Assessed Joint Damage and Type II Collagen Degradation Products Are Linked to Disease Progression.Frontiers in neuroscience · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aims to discover that the urinary C-terminal telopeptide of type II collagen (uCTX-II) levels differ between osteoarthritis (OA) patients and healthy individuals (controls). According to this difference, we may conclude that uCTX-II can be a biomarker for OA diagnosis.
methodsWe searched MEDLINE and EMBASE databases updated to 2014 to find literature on OA biomarkers. We retrieved the publications that met the required criterion. Literature quality was assessed according to the Newcastle-Ottawa Scale. Publication bias was assessed by Begg's test and Egger's test with the software STATA version 12.0. The weighted mean difference (WMD) was calculated, and the subgroup analysis was completed using STATA 12.0.
resultsSix publications were included in our analysis. The WMD for OA patients versus the controls was 83.05, which was within the 95% confidence interval. For subgroup analysis, the WMD of patients with severe OA was 119.92, whereas that of patients with mild OA was 28.07.
conclusionsuCTX-II levels were higher in OA patients than in controls, subgroup analysis revealed that the uCTX-II levels rised with the OA severity, the heterogeneity originated from different levels of OA severity, These results showed that uCTX-II would be a promising clinical biomarker in OA diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.